US Archives - Page 63 of 100 - European Medical Journal

RBC Transfusions: New Guidelines for ICU Care

New evidence-based guidelines for red blood cell (RBC) transfusions in critically ill patients have been released, offering critical care practitioners a roadmap to optimize patient outcomes.

Knowledge Gaps Found in Antiseizure Medications and Birth Control: AES 2024

The study surveyed 107 people, aged 18 to 49, who were taking ASMs, asking about their medication use, pregnancy plans, and contraceptive methods…

Risk-Reducing Surgery for BRCA Carriers: SABCS 2024

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

COMET Trial Suggests Active Monitoring for Low-Risk DCIS: SABCS 2024

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

Melanoma Survivors Face 57% Increased Risk of Malignancies

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.

Treg Cells: Helpers or Harmers in Arthritis?

Regulatory T (Treg) cells are vital for immune system balance, preventing autoimmune diseases by suppressing inflammation.

Epilepsy Prevention Using ARBs After Stroke: AES 2024

Stroke survivors with hypertension may have a new ally in reducing their risk of post-stroke epilepsy (PSE): angiotensin receptor blockers (ARBs).

Next-Gen SERD Improves Outcomes in Resistant Breast Cancer: SABCS 2024

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

How Circadian Rhythms Impact Glioblastoma Growth

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

Interview: Daniel Wallace

In the late 1980s and early 1990s, we were among the first to suggest that interleukin-6 played a role in lupus. It’s not specific just…